Outcome measures in SMA

Spinal Muscular Atrophy Microchapters
Home
Patient Info
Overview
Epidemiology and Demographics
Risk Factors
Screening
Other forms
Molecular Biology
Genetics
Types
Diagnosis
Diagnosis
Full Differential Diagnosis
Symptom
Physical Examination
Electrolyte & Biomarker Studies
Electrocardiogram
Chest X Ray
MRI and CT
Echocardiography or Ultrasound
Other Imaging Findings
Pathology
Other Diagnostic Studies
Treatment
Outcome measures
Therapeutics development
Indications For Surgery
Research
Pre-Operative Assessment
Post-Operative Assessment
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Outcome measures in SMA Resources
Most recent articles on Outcome measures in SMA
Most cited articles on Outcome measures in SMA
Review articles on Outcome measures in SMA
Review articles on Outcome measures in SMA
CME Programs on Outcome measures in SMA
Powerpoint slides on Outcome measures in SMA
Images of Outcome measures in SMA
Ongoing Trials on Outcome measures in SMA at Clinical Trials.gov
US National Guidelines Clearinghouse on Outcome measures in SMA
NICE Guidance on Outcome measures in SMA
FDA on Outcome measures in SMA
CDC on Outcome measures in SMA
Outcome measures in SMA in the news
Blogs on Outcome measures in SMA
Directions to Hospitals Treating Outcome measures in SMA
Risk calculators and risk factors for Outcome measures in SMA

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [3]

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [4] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

There is currently no cure for spinal muscular atrophy. There has been great interest in identifying agents that can increase the amount of full- length SMN protein by upregulating expression of the SMN2 gene. Many clinical trials are ongoing to find the most reliable outcome measures.

Several new outcome measures have shown encouraging results and helped in designing future clinical trials. Some of them currently used in clinical trials are as follows –

• Quantitative muscle ultrasound

• The Six-Minute Walk Test (6MWT) – In case of ambulatory SMA patients.

• 10 minute walk/run test

• The Hammersmith Motor Scale

• The Hammersmith Functional Motor Scale Expanded (HFMSE)

• Knee flexor strength test

• The Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND)

• The Gross Motor Function Measurement

• Motor unit number estimation (MUNE)

• Compound motor action potential (CMAP) amplitude

• Serologic biomarkers (SMN mRNA and protein levels)